A number of firms have modified their ratings and price targets on shares of Ionis Pharmaceuticals (NASDAQ: IONS) recently: 2/8/2024 – Ionis Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating. 2/1/2024 – Ionis Pharmaceuticals had its price target raised by analysts at JPMorgan Chase & Co. from $52.00 […]
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) EVP Eric Swayze sold 10,773 shares of the stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $52.00, for a total transaction of $560,196.00. Following the transaction, the executive vice president now owns 32,516 shares in the company, valued […]
Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) have received a consensus rating of “Moderate Buy” from the fourteen research firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, four have given a hold rating, seven have given a buy rating and one […]
StockNews.com upgraded shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) from a sell rating to a hold rating in a research note released on Tuesday. Other analysts also recently issued reports about the stock. Raymond James initiated coverage on shares of Ionis Pharmaceuticals in a research report on Thursday, September 28th. They set a strong-buy […]
StockNews.com upgraded shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) from a sell rating to a hold rating in a report published on Tuesday. IONS has been the subject of a number of other reports. The Goldman Sachs Group increased their price target on Ionis Pharmaceuticals from $25.00 to $28.00 and gave the company a […]